SLS - CIK 0001390478
SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0.00 for fiscal year 2023, as filed in its audited annual report with the SEC.
| Fiscal year | Revenue | Change |
|---|---|---|
| FY 2023 | $0.00 | -100.0% |
| FY 2022 | $1.00M | -86.8% |
| FY 2021 | $7.60M | +300.0% |
| FY 2020 | $1.90M | - |
| FY 2019 | $0.00 | -100.0% |
| FY 2014 | $9.32M | +274.7% |
| FY 2013 | $2.49M | - |
| FY 2012 | $0.00 | - |
| FY 2011 | $0.00 |
SELLAS Life Sciences Group, Inc. (SLS) reported revenue of $0.00 for fiscal year 2023, as filed in its audited annual report with the SEC.
Between fiscal 2011 and fiscal 2023, SELLAS Life Sciences Group, Inc.'s revenue grew from $0.00 to $0.00.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |